• Explore /
  • Poster
  • / Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors.

Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors.

Abstract Poster

Authors

Ulka Vaishampayan

Ulka N. Vaishampayan

Wayne State University, Detroit, MI

Ulka N. Vaishampayan , Mayer N. Fishman , Daniel C. Cho , Christopher J. Hoimes , Vamsidhar Velcheti , David F. McDermott , William J. Slichenmyer , Emily Putiri , Heather Losey , Sean Rossi , Marc S. Ernstoff

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Immunotherapy and Tumor Immunobiology

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Cellular Immmunotherapy

Clinical Trial Registration Number

NCT02799095

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS2649)

DOI

10.1200/JCO.2019.37.15_suppl.TPS2649

Abstract #

TPS2649

Poster Bd #

290b

Abstract Disclosures

Similar Posters

First Author: Sarina Anne Piha-Paul

Poster

2022 ASCO Genitourinary Cancers Symposium

Nemvaleukin alfa in patients with advanced renal cell carcinoma: ARTISTRY-1.

Nemvaleukin alfa in patients with advanced renal cell carcinoma: ARTISTRY-1.

First Author: Emiliano Calvo

First Author: Valentina Boni

First Author: Iwona A. Lugowska